Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 5, 1996, Pages 475-490

  Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclosporine; CYP3A metabolism; Drug interaction; Terfenadine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; MACROLIDE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TERFENADINE; UNINDEXED DRUG;

BIOTRANSFORMATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; LIVER; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; TERFENADINE; VARIATION (GENETICS);

EID: 0030428256     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353475     Document Type: Review

References (38)

1. F. P. Guengerich. Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, Plenum Press, New York, 1995, pp. 473-535.
2. S. A. Wrighton, M. VandenBranden, and B. J. Ring. The human drug metabolizing cytochromes P450. J. Pharmacokin. Biopharm. 24:461-473 (1996).
3. P. B. Watkins. Case studies - the gut. J. Pharmacokin. Biopharm. (in press).
4. E. R. Schuetz, J. D. Schuetz, W. M. Grogan, A. N. Fejes-Troth, G. Fejes-Troth, J. Raucy, P. Guezelian, K. Gionela, and C. O. Watlington. Expression of cytochrome P4503A in amphibian, rat and human kidney. Arch. Biochem. Biophys. 294:206-214 (1992).
5. F. P. Guengerich. In vitro techniques for studying drug metabolism. J. Pharmacokin. Biopharm. 24:521-533 (1996).
6. C.-Y. Wu, L. Z. Benet, M. F. Herbert, S. K. Gupta, M. Rowland, D. Y. Gomez, and V. J. Wacher. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin. Pharmacol. Ther. 58:492-497 (1995).
7. K. E. Thummel, D. O'Shea, M. F. Paine, D. D. Shen, K. L. Lunze, J. D. Perkins, and G. R. Wilkinson. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59:491-502 (1996).
8. D. Reimers and A. Ježek. Rifampicin und andere antituberkulotika bei gleichzeitiger oraler kontrazeption. Prax. Pneumol. 25:255-262 (1971).
9. D. Janz and D. Schmidt. Anti-epileptic drugs and failure of oral contraceptives. Lancet 1:1113 (1974).
10. D. G. Bailey, J. M. O. Arnold, and J. D. Spence. Grapefruit juice and drugs: How significant is the interaction? Clin. Pharmacokin. 26:91-98 (1994).
11. M. P. Ducharme, L. H. Warbasse, and D. J. Edwards. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:485-491 (1995).
12. H. H. T. Kupferschmidt, H. R. Ha, W. H. Ziegler, P. J. Meier, and S. Krähenbuhl. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58:20-28 (1995).
13. R. Z. Harris, L. Z. Benet, and J. B. Schwartz. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222-239 (1995).
14. G. Castañeda-Hernández, C. Hoyo-Vadillo, J. A. Palma-Aguirre, and F. J. Flores-Murrieta. Pharmacokinetics of oral nifedipine in different populations. J. Clin. Pharmacol. 33:140-145 (1993).
15. A. Sowunmi, T. J. Rashid, O. O. Akinyinka, and A. G. Renwick. Ethnic differences in nifedipine kinetics: Comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol. 40:489-493 (1995).
16. C. C. Peck, R. A. Temple, and J. M. Collins. Understanding consequences of concurrent therapies. J. Am. Med. Assoc. 269:1550-1552 (1993).
17. D. A. Gartiez, R. H. Hook, B. J. Walker, and R. A. Okerholm. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim Forsch. 32:1185-1190 (1982).
18. R. A. Okerholm, D. L. Weiner, R. H. Hook, B. J. Walker, G. A. Leeson, S. A. Biedenbach, M. J. Cawein, T. D. Dusebout, G. J. Wright, M. Myers, V. Schindler, and C. E. Cook. Bioavailability of terfenadine in man. Biopharm. Drug Dispos. 2:185-190 (1981).
19. R. L. Woosley, Y. Chen, J. P. Freiman, and R. A. Gillis. Mechanism of the cardiotoxic actions of terfenadine. J. Am. Med. Assoc. 269:1532-1536 (1993).
20. T. K. Daneshmend and D. W. Warnock. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokin. 14:13-34 (1988).
21. P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. J. Am. Med. Assoc. 269:1513-1518 (1993).
22. S. Pohjola-Sintonen, M. Viitasalo, L. Toivonen, and P. Neuvonen. Intraconazole prevents terfenadine metabolism and increase risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45:191-193 (1993).
23. P. K. Honig, D. C. Wortham, R. Hull, K. Zamani, J. E. Smith, and L. R. Cantilena. Intraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33:1201-1206 (1993).
24. P. K. Honig, D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Phamacol. Ther. 53:630-636 (1993).
25. P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231-238 (1992).
26. P. K. Honig, D. C. Wortham, K. Zamani, and L. R. Cantilena. Comparison on the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 7:148-156 (1994).
27. M. Eller, M. Stoltz, R. Okerholm, and B. McNutt. Effect of hepatic disease on terfenadine and terfenadine metabolite pharmacokinetics. Clin. Pharmacol. Ther. 53:162 (1994).
28. B. P. Monahan, C. L. Ferguson, E. S. Killeavy, B. K. Lloyd, J. Troy, and L. R. Cantilena. Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 264:2788-2790 (1990).
29. S. M. Tsunoda and F. T. Aweeka. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin. Pharmacokin. 30:107-140 (1996).
30. T. Kronbach, V. Fischer, and U. A. Meyer. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43:630-635 (1988).
31. J. Combalbert, I. Fabre, G. Fabre, I. Dalet, J. Derancourt, J. P. Cano, and P. Maurel. Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab. Dispos. 17:197-207 (1989).
32. G. C. Yee and T. R. McGuire. Pharmacokinetic drug interactions with cyclosporin. Clin. Pharmacokin. 19:319-332, 400-415 (1990).
33. L. Pichard, I. Fabre, G. Fabre, J. Domergue, B. S. Aubert, G. Mourad, and P. Maurel. Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18:595-606 (1990).
34. A. D. Rodrigues. Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochem. Pharmacol. 48:2147-2156 (1994).
35. P. Skett, C. Tyson, A. Guillouzo, and P. Maier. Report on the international workshop on the use of human in vitro liver preparations to study drug metabolism in drug development. Biochem. Pharmacol. 50:280-285 (1995).
36. L. Z. Benet. The hypothesized preclinical use of drug metabolism isoforms. J. Pharmacokin. Biopharm. (in press).
37. R. L. Smith and R. R. Shah. Basic biochemical features and molecular genetics of CYP2D6. J. Pharmacokin. Biopharm. (in press).
38. P. B. Watkins. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184 (1994).